Roche's Ocrevus for two forms of MS accepted for review by EMA and FDA

The marketing application submitted by Swiss pharma giant Roche (ROG: SIX) for Ocrevus (ocrelizumab) to treat two forms of multiple sclerosis has been accepted for review by both the European and US regulators.

The European Medicines Agency has validated the company’s Marketing Authorization Application of the drug for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), confirming that the submission is complete and under review by the agency’s Committee for Medicinal Products for Human Use.

Across the Atlantic, the FDA has also accepted for review Roche’s Biologics License Application for Ocrevus to treat the same two conditions.